ArticleCytoJournal2025
Ubiquitin C-terminal hydrolase L5 promotes the development of renal cell carcinoma through the glycolysis mediated by the phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin pathway.
Article in CytoJournal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Renal cell carcinoma (RCC) is a prevalent malignant tumor of the kidney that has considerable heterogeneity and intricate molecular pathways. Incidence and death rates associated with kidney cancer have been increasing steadily. Consequently, investigating its molecular basis and identifying new biomarkers for targeted therapies have become important. Ubiquitin C-terminal hydrolase L5 (UCHL5) has an effect on tumor initiation and progression. This study aims to explore the role of UCHL5 in promoting RCC development and identify related molecular mechanisms. Material and Methods: Quantitative real-time polymerase chain reaction and Western blot (WB) analyses were employed to measure UCHL5 expression. Stable UCHL5 overexpression and knockdown cell lines were generated using lentiviral transfection in 786-O cells. Colony formation and 5-ethynyl-2'-deoxyuridine assays were used to assess cell proliferation. Cell migration was evaluated using scratch assays, while invasion capacity was determined by Transwell assays. Commercial kits were utilized to quantify glucose consumption and lactate production. WB was applied to detect proteins related to glycolysis and components of the Phosphoinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway. The function of UCHL5 in RCC cells was validated Results: The expression of UCHL5 increased in RCC cell lines ( Conclusion: UCHL5 activates the PI3K/AKT/mTOR cascade, which enhances the glycolysis of RCC cells and promotes the development of renal cancer. This study provides insights into the molecular mechanisms underlying the oncogenic role of UCHL5 in RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.